利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.037 秒)

    Animal with gene hypoexpression
    3.
    发明授权
    Animal with gene hypoexpression 失效
    动物与基因低表达

    公开(公告)号：US07462757B2

    公开(公告)日：2008-12-09

    申请号：US10478466

    申请日：2002-05-21

    申请人： Tomoko Satomi ,  Ryuichi Tozawa ,  Mitsugu Nakata ,  Yoshitaka Yasuhara ,  Yoshio Taniyama

    发明人： Tomoko Satomi ,  Ryuichi Tozawa ,  Mitsugu Nakata ,  Yoshitaka Yasuhara ,  Yoshio Taniyama

    IPC分类号： A01K67/00 ,  A01K67/027 ,  G01N33/00

    CPC分类号： C12N15/907 ,  A01K2217/075 ,  C12N2517/02

    摘要： The present invention relates to non-human animal embryonic stem cells in which a lecithin:cholesterol acyltransferase-like lysophospholipase endogenous gene is inactivated; non-human animals deficient in expression of LLPL gene; methods of screening for prophylactics and/or therapeutic drug using the cells or the animals; and prophylactics and/or therapeutic drug obtainable by the screening.The non-human animal ES cells of the invention in which their LLPL gene is inactivated are very useful in creating non-human animals deficient in expression of LLPL gene. The LLPL expression deficient non-human animals of the invention can be disease models for such diseases caused by insufficiency of the biological activities of LLPL since the animals lack various biological activities inducible by LLPL. Therefore, the animals of the invention are useful in screening for prophylactics and/or therapeutic drug for various diseases resulting from LLPL deficiency, as well as in elucidating the causes of LLPL-related diseases and examining therapeutic methods for such diseases. The screening methods of the invention are capable of efficiently screening for prophylactics and/or therapeutic drug for various diseases resulting from LLPL deficiency.

    摘要翻译： 本发明涉及非人动物胚胎干细胞，其中卵磷脂：胆固醇酰基转移酶样溶血磷脂酶内源基因失活; 非人类动物缺乏LLPL基因的表达; 使用细胞或动物筛选预防和/或治疗药物的方法; 以及通过筛选可获得的预防和/或治疗药物。 其LLPL基因失活的本发明的非人动物ES细胞非常有用于产生缺乏LLPL基因表达的非人动物。 本发明的LLPL表达缺陷型非人动物可以是LLPL生物活性不足引起的疾病的疾病模型，因为动物缺乏由LLPL诱导的各种生物活性。 因此，本发明的动物可用于筛选由LLPL缺乏引起的各种疾病的预防和/或治疗药物，以及阐明LLPL相关疾病的原因并检查这些疾病的治疗方法。 本发明的筛选方法能够有效筛选由LLPL缺乏引起的各种疾病的预防和/或治疗药物。

    Novel protein, production and use thereof
    4.
    发明申请
    Novel protein, production and use thereof 审中-公开
    新型蛋白质，其生产和使用

    公开(公告)号：US20060035835A1

    公开(公告)日：2006-02-16

    申请号：US11242459

    申请日：2005-10-03

    申请人： Yoshio Taniyama ,  Shunbun Kita ,  Tomoko Satomi

    发明人： Yoshio Taniyama ,  Shunbun Kita ,  Tomoko Satomi

    IPC分类号： A61K38/17 ,  C07K14/705 ,  C07K16/28 ,  C07H21/04 ,  C12P21/06

    CPC分类号： A61K48/00 ,  A61K38/00 ,  C07K14/47

    摘要： The present invention relates to a novel SSD (sterol-sensing domain)-containing protein derived from human liver, human testis and human brain, or a salt thereof, and a DNA encoding the same. Studies on the tissue-specificity of the protein expression, the expression change depending the intracellular cholesterol level, production of the transformant, and the site-specific expression in brain regions of a patient with Alzheimer's disease are disclosed.

    摘要翻译： 本发明涉及一种衍生自人肝，人睾丸和人脑或其盐的新型SSD（固醇感受结构域）的蛋白质及其编码的DNA。 公开了关于蛋白质表达的组织特异性，依赖于细胞内胆固醇水平的表达变化，转化体的产生以及阿尔茨海默氏病患者的脑区域中的位点特异性表达的研究。